kras mutation and glutathion The roles of in cancer metabolism, tumor microenvironment clinical therapy | Molecular Cancer KRAS | OriGene Technologies Inc.
KRAS OriGene Technologies Inc. KRAS mutation: from undruggable to druggable in cancer Signal Transduction and Targeted Therapy Uncovering new therapeutic targets for a common KRAS mutation behind cancer JCI Suppression of the SLC7A11 glutathione axis causes synthetic lethality in KRAS mutant lung adenocarcinoma Research advances in the treatment of KRAS mutant colorectal cancer from Prof. Guoquan Gao's group at Zhongshan School of Medicine SUN YAT SEN UNIVERSITY Frontiers KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
Pay in 4 interest-free payments of $6.36 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9





